The FDA blend therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-one bacterial infections whose virus is now suppressed (< 50 copies/ml) on a secure regimen for a minimum of six months, without the need of record of therapy failure and no recognised substitutions related to resistance https://hivhub.in/product/viropil-tablet/